A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy

A Phase II Study of BIBF1120 in Recurrent and Platinum-Sensitive Small Cell Lung Cancer (SCLC)

This study is being done to evaluate the good and bad effects of BIBF1120 in recurrent, platinum-sensitive small cell lung cancer patients and to see if BIBF1120 may or may not be more effective and better tolerated than standard therapy.

The purpose of this study is to:

• Find out the proportion of patients with their small small cell lung cancer controlled for at least 90 days after treatment with BIBF1120
• Compare the response rate, survival and side effects of BIBF1120 in recurrent, platinum-sensitive small cell lung cancer patients
• Identify a group of patients who will benefit the most from BIBF1120 In this study, patients will receive BIBF1120 at 200 mg twice daily continuously. A cycle will be 21 days. During treatment, the dose of BIBF1120 will be held or reduced to lower doses if patients do not tolerate it well or if the doctors are concerned about the side effects of BIBF1120 on individual patients.

Study Overview

• Status: Withdrawn
• Conditions: Small Cell Lung Cancer; Platinum-sensitive
• Intervention / Treatment: Drug: BIBF1120

Detailed Description

This study is being done to evaluate the effects of BIBF1120 in recurrent, platinum-sensitive small cell lung cancer patients.

Primary Objectives:

• To investigate the efficacy and safety of a novel VEGFR-2 and FGFR-1 targeting agent, BIBF1120, in previously treated, platinum-sensitive small cell lung cancer patients.

Secondary Objectives:

• To correlate response to the apoptotic biomarkers, Bcl-XL/Bcl-2 and FDGR-1 amplification.
• To correlate response with baseline FLT-PET SUV uptake and change in FLT-PET SUV uptake.

All eligible patients will be treated with 200 mg bid of BIBF1120 daily and 21 days will be considered as one cycle

• Study Type: Interventional
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • Alberta
    • Edmonton, Alberta, Canada, T6G 1Z2
      • Cross Cancer Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age > 18
• Recurrent and platinum-sensitive small cell lung cancer (SCLC): defined as those patients with SCLC recurrence at least 3 months from the last dose of platinum-based chemotherapy. Definition of platinum-sensitive disease is patient with at least 3 months of progression-free duration after finishing first-line platinum-based chemotherapy.
• Histological diagnosis of small cell lung cancer (including Oat cell carcinoma, small cell neuroendocrine tumor). Patients with archival tumor samples will be collected for further translational studies. For those who have no archival tumor samples, without due harm, a fresh biopsy can be obtained.
• As progression-free survival (PFS) or PFS rate is the endpoint, all patients enrolled must have measurable (per RECIST 1.1 Criteria) radiological progression of disease on radiological investigations.
• ECOG performance status of 0-2
• Adequate hematological function defined as hemoglobin > 90 g/L, ANC > 1500/uL and platelets > 100, 000/uL.
• Adequate renal function defined as creatinine < 1.5 x ULN or creatinine clearance > 45 mL/min (Cockcroft-Gault).
• Adequate liver function defined as AST/ALT < 1.5 x ULN or < 2.5 x ULN in the presence of liver metastases and total bilirubin < 1.5 x ULN.
• INR/PTT < 1.5 x ULN
• Left ventricular function by echocardiogram > institutional lower limit of normal.
• Women of childbearing potential and all must use adequate birth control. A serum pregnancy test must be performed within 72 hours from enrollment for all eligible women of childbearing potential.
• The absence of any significant psychiatric and medical condition that will potentially affect compliance to therapy or will be adversely affected by the experimental therapy.
• Able to swallow oral medication.
• Life expectancy of at least 12 weeks.
• All patients enrolled must have at least one prior platinum-based chemotherapy regimen in either the limited staged or extensive staged setting.
• All patients must have a blood pressure of 150/90 mm Hg or less at the time of enrollment. Patients who have been on anti-hypertensives will be eligible if their blood pressure is less than 150/90 mm Hg on enrollment with no increase of their anti-hypertensive medications for the 2 weeks prior to enrollment.
• Signed and dated written informed consent prior to enrollment in the study in accordance with ICH-GCP guidelines and to the local legislation.

Exclusion Criteria:

• Symptomatic, untreated brain metastasis. Patients with asymptomatic brain metastasis defined as those with no CNS symptoms, no concurrent significant edema on CT or MRI of the brain and no concurrent corticosteroid therapy will be eligible. Those with leptomeningeal disease will NEVER be eligible due to overall poor prognosis. Patients who have treated brain metastasis without concurrent corticosteroid and anti-convulsant therapy and without progression on CT or MRI scan of the brain for at least 60 days will be eligible
• Symptoms of congestive heart failure, myocardial infarction or angina within 6 months.
• Previous allergy to VEGR or FGF tyrosine kinase inhibitor.
• Current therapeutic coumadin treatment.
• History of pulmonary embolism, deep vein thrombosis within the past 1 year. Patients with any prior history of peripheral arterial thrombosis are not eligible.
• History of hemoptysis of more than 5 mL per episode or more than 10 mL/week in total within the past 3 months.
• History of bleeding disorder.
• Surgery, hormonal therapy, chemotherapy, radiation therapy or other investigational agents within 28 days of enrollment, with the exception of low dose palliative RT (20 Gy or less involving < 10% bone marrow).
• History of recent gastrointestinal bleeding, obstruction or perforation of malabsorption syndrome.
• History of QT c > 480 ms on ECG or hsitory of cardiac arrhythmia or treatment with anti-arrhythmic except for atrial fibrillation or any history of second- or third-degree heart block.
• Diagnosis of HIV infection or AIDS.
• Diagnosis of interstitial lung disease.
• Radiotherapy (except extremities) within the past 2 months prior to baseline imaging.
• Persistence of clinically relevant therapy-related toxicity from previous chemotherapy and/or radiotherapy.
• Leptomeningeal disease.
• Radiographic evidence of cavitary or necrotic tumors.
• Centrally located tumors with radiographic evidence (CT or MRI) of local invasion of major blood vessels. As small cell lung cancer is often presented as a mediastinal mass, compression of mediastinal blood vessels will be allowed.
• Therapeutic anticoagulation (except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous device) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid < 325 mg per day).
• Major injuries within the past 10 days prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study period.
• History of clinically significant haemorrhagic or thromboembolic event in the past 6 months.
• Proteinuria CTCAE grade 2 or greater.
• Other malignancies within the past 5 years other than basal cell skin cancer or carcinoma in situ of the cervix.
• Active serious infections, in particular if requiring systemic antibiotic or antimicrobial therapy.
• Active or chronic hepatitis C and/or B infection.
• Patients who are sexually active and unwilling to use a medically acceptable method of contraception (e.g. such as implants, injectables, combined oral contraceptives, some intrauterine devices or vasectomised partner for participating females, condoms for participating males) during the trial and for at least 3 months after end of active therapy. Patients who are pregnant and/or lactating are not eligible.
• Active alcohol or drug abuse.
• Significant weight loss (> 10% of body weight) within past 6 months prior to inclusion into the trial

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: BIBF1120; BIBF1120 200 mg twice daily continuously	Drug: BIBF1120; BIBF1120 is a VEGFR, FGFR and PDGFR inhibitor; Other Names: Nintedanib

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Disease control rate	90 days

Secondary Outcome Measures

Outcome Measure	Time Frame
Disease response rate	every 6 weeks

Collaborators and Investigators

• Sponsor: AHS Cancer Control Alberta
• Collaborators: Boehringer Ingelheim; Cross Cancer Institute
• Investigators: Principal Investigator: Quincy Chu, MD, Alberta Health Services

Study record dates

Study Major Dates

• Study Start: July 1, 2014
• Primary Completion (Actual): July 1, 2016
• Study Completion (Actual): July 1, 2016

Study Registration Dates

• First Submitted: May 29, 2014
• First Submitted That Met QC Criteria: May 29, 2014
• First Posted (Estimate): June 2, 2014

Study Record Updates

• Last Update Posted (Estimate): July 6, 2016
• Last Update Submitted That Met QC Criteria: July 4, 2016
• Last Verified: July 1, 2016

More Information

Terms related to this study

• Keywords: Small cell lung cancer; nintedanib; platinum-sensitive; BIBF1120
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Immune System Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Hypersensitivity; Lung Neoplasms; Small Cell Lung Carcinoma; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Protein Kinase Inhibitors; Nintedanib
• Other Study ID Numbers: BIBF-SCLC-001